Antineoplastics (BCR-ABL TKIs)
- Target BCR-ABL in Philadelphia+ leukemia
- Transformative therapy for chronic-phase CML
- Imatinib is historic prototype
- Later TKIs overcome resistance/intolerance
- Toxicities differ: vascular, pleural, QT, metabolic
- CYP3A interactions are common
- Response is followed with molecular BCR-ABL
Class at a glance
- Target BCR-ABL in Philadelphia+ leukemia
Practical pearls
- Imatinib is historic prototype
Pharmacology
- CYP3A interactions are common
Members / distinctions
- Transformative therapy for chronic-phase CML
- Later TKIs overcome resistance/intolerance
- Response is followed with molecular BCR-ABL
Safety / monitoring
- Toxicities differ: vascular, pleural, QT, metabolic
Self-check
- What major toxicities vary among BCR-ABL TKIs?
Vascular, pleural, QT, and metabolic toxicities. - How is BCR-ABL TKI response followed?
Molecular BCR-ABL testing.
Drugs in this class (5)
Antineoplastics (BCR-ABL TKIs) prescription history
Animated chart of estimated U.S. prescriptions per year, Tyrosine kinase inhibitors (2001–2026). ABL inhibitors highlighted from 2001.
All drug classes · Open Antineoplastics (BCR-ABL TKIs) in the interactive console ↗